Effect of eribulin on epithelial–mesenchymal transition plasticity in metastatic breast cancer: An exploratory, prospective study
Genes to Cells · 2023-05 · 28 (5) · 364-373
DOI: 10.1111/gtc.13019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes to Cells, online erschienen am 12.03.2023. Verfasst von Takanori Hayashi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Fujita Health University.
Abstract (Originalsprache)
Epithelial–mesenchymal transition (EMT) plays a pivotal role in cancer metastasis and treatment resistance, which worsens prognosis. In phase III trials, eribulin improved overall survival in metastatic breast cancer (MBC) patients. In preclinical studies, eribulin suppressed EMT. However, clinical data on the use of eribulin for MBC patients are limited. In this exploratory, prospective study, we examined the effect of eribulin on EMT in MBC patients. Twenty‐two patients aged 44–82 years with recurrent breast cancer or MBC were treated with eribulin. Breast cancer tissue samples were obtained before treatment and on Day 15 ± 5 of the first cycle of eribulin treatment. EMT markers (E‐cadherin, claudin‐3, vimentin, and N‐cadherin) were analyzed using western blotting. EMT changes were evaluated based on the ratio of epithelial to mesenchymal markers before and after treatment in individual tumors. E‐cadherin/vimentin, claudin‐3/vimentin, E‐cadherin/N‐cadherin, and claudin‐3/N‐cadherin ratios were significantly higher after treatment ( p = .007, p = .005, p = .006, and p = .011, respectively). Based on E‐cadherin/vimentin, 65.0% of tumors shifted to an epithelial phenotype, as compared to 66.7% based on claudin‐3/vimentin, 84.6% based on E‐cadherin/N‐cadherin, and 71.4% based on claudin‐3/N‐cadherin ratios. Thus, our results showed that eribulin suppressed EMT in breast cancer tissues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
- Department of Breast Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi, Japan.
- Department of Pathology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
- Division of Breast and Endocrine Surgery, Department of Surgery, Aichi Medical University, Nagakute, Aichi, Japan.
- Department of Surgery, Fujita Health University School of Medicine, Nagoya, Aichi, Japan.
ORCID-Profile: Takanori Hayashi, Toshiaki Utsumi
Förderung
- Fujita Health University
Zitieren
APA
Hayashi, T., Kobayashi, N., Ushida, K., Asai, N., Nakano, S., Fujii, K., Ando, T., & Utsumi, T. (2023). Effect of eribulin on epithelial–mesenchymal transition plasticity in metastatic breast cancer: An exploratory, prospective study. Genes to Cells, 28(5), 364-373. https://doi.org/10.1111/gtc.13019
Vancouver
Hayashi T, Kobayashi N, Ushida K, Asai N, Nakano S, Fujii K, et al. Effect of eribulin on epithelial–mesenchymal transition plasticity in metastatic breast cancer: An exploratory, prospective study. Genes to Cells. 2023;28(5):364-373. doi:10.1111/gtc.13019
BibTeX
@article{Hayashi2023,
author = {Hayashi, Takanori and Kobayashi, Naomi and Ushida, Kaori and Asai, Naoya and Nakano, Shogo and Fujii, Kimihito and Ando, Takahito and Utsumi, Toshiaki},
title = {Effect of eribulin on epithelial–mesenchymal transition plasticity in metastatic breast cancer: An exploratory, prospective study},
journal = {Genes to Cells},
year = {2023},
volume = {28},
number = {5},
pages = {364--373},
doi = {10.1111/gtc.13019}
}
EUVIMED